These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 31443604)

  • 21. The tumour-targeting human L19-IL2 immunocytokine: preclinical safety studies, phase I clinical trial in patients with solid tumours and expansion into patients with advanced renal cell carcinoma.
    Johannsen M; Spitaleri G; Curigliano G; Roigas J; Weikert S; Kempkensteffen C; Roemer A; Kloeters C; Rogalla P; Pecher G; Miller K; Berndt A; Kosmehl H; Trachsel E; Kaspar M; Lovato V; González-Iglesias R; Giovannoni L; Menssen HD; Neri D; de Braud F
    Eur J Cancer; 2010 Nov; 46(16):2926-35. PubMed ID: 20797845
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mechanisms of Vasculogenic Mimicry in Ovarian Cancer.
    Ayala-Domínguez L; Olmedo-Nieva L; Muñoz-Bello JO; Contreras-Paredes A; Manzo-Merino J; Martínez-Ramírez I; Lizano M
    Front Oncol; 2019; 9():998. PubMed ID: 31612116
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Syndecan-1 expression by stromal fibroblasts promotes breast carcinoma growth in vivo and stimulates tumor angiogenesis.
    Maeda T; Desouky J; Friedl A
    Oncogene; 2006 Mar; 25(9):1408-12. PubMed ID: 16247452
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A novel human anti-syndecan-1 antibody inhibits vascular maturation and tumour growth in melanoma.
    Orecchia P; Conte R; Balza E; Petretto A; Mauri P; Mingari MC; Carnemolla B
    Eur J Cancer; 2013 May; 49(8):2022-33. PubMed ID: 23352437
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Epithelial-to-endothelial transition and cancer stem cells: two cornerstones of vasculogenic mimicry in malignant tumors.
    Sun B; Zhang D; Zhao N; Zhao X
    Oncotarget; 2017 May; 8(18):30502-30510. PubMed ID: 27034014
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Correlation between bacterial L-form infection, expression of HIF-1α/MMP-9 and vasculogenic mimicry in epithelial ovarian cancer].
    Yu L; Wu SW; Zhou L; Song WQ
    Sheng Li Xue Bao; 2012 Dec; 64(6):657-65. PubMed ID: 23258329
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy of trebananib (AMG 386) in treating epithelial ovarian cancer.
    Al Wadi K; Ghatage P
    Expert Opin Pharmacother; 2016; 17(6):853-60. PubMed ID: 26933765
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Radioimmunotherapy of head and neck cancer xenografts using 131I-labeled antibody L19-SIP for selective targeting of tumor vasculature.
    Tijink BM; Neri D; Leemans CR; Budde M; Dinkelborg LM; Stigter-van Walsum M; Zardi L; van Dongen GA
    J Nucl Med; 2006 Jul; 47(7):1127-35. PubMed ID: 16818947
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The immunocytokine F8-IL2 improves the therapeutic performance of sunitinib in a mouse model of renal cell carcinoma.
    Frey K; Schliemann C; Schwager K; Giavazzi R; Johannsen M; Neri D
    J Urol; 2010 Dec; 184(6):2540-8. PubMed ID: 21030045
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Syndecan-1 suppresses epithelial-mesenchymal transition and migration in human oral cancer cells.
    Wang X; He J; Zhao X; Qi T; Zhang T; Kong C
    Oncol Rep; 2018 Apr; 39(4):1835-1842. PubMed ID: 29484435
    [TBL] [Abstract][Full Text] [Related]  

  • 31. cRGD inhibits vasculogenic mimicry formation by down-regulating uPA expression and reducing EMT in ovarian cancer.
    Tang J; Wang J; Fan L; Li X; Liu N; Luo W; Wang J; Wang Y; Wang Y
    Oncotarget; 2016 Apr; 7(17):24050-62. PubMed ID: 26992227
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hypoxia induced epithelial-mesenchymal transition and vasculogenic mimicry formation by promoting Bcl-2/Twist1 cooperation.
    Liu K; Sun B; Zhao X; Wang X; Li Y; Qiu Z; Gu Q; Dong X; Zhang Y; Wang Y; Zhao N
    Exp Mol Pathol; 2015 Oct; 99(2):383-91. PubMed ID: 26318343
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-lasting antitumor effects provided by radiotherapy combined with the immunocytokine L19-IL2.
    Rekers NH; Zegers CM; Germeraad WT; Dubois L; Lambin P
    Oncoimmunology; 2015 Aug; 4(8):e1021541. PubMed ID: 26405576
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Endostatin combined with radiotherapy suppresses vasculogenic mimicry formation through inhibition of epithelial-mesenchymal transition in esophageal cancer.
    Chen X; Zhang H; Zhu H; Yang X; Yang Y; Yang Y; Min H; Chen G; Liu J; Lu J; Cheng H; Sun X
    Tumour Biol; 2016 Apr; 37(4):4679-88. PubMed ID: 26511968
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Radioimmunotherapy of solid tumors by targeting extra domain B fibronectin: identification of the best-suited radioimmunoconjugate.
    Berndorff D; Borkowski S; Sieger S; Rother A; Friebe M; Viti F; Hilger CS; Cyr JE; Dinkelborg LM
    Clin Cancer Res; 2005 Oct; 11(19 Pt 2):7053s-7063s. PubMed ID: 16203802
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Characterisation and radioimmunotherapy of L19-SIP, an anti-angiogenic antibody against the extra domain B of fibronectin, in colorectal tumour models.
    El-Emir E; Dearling JL; Huhalov A; Robson MP; Boxer G; Neri D; van Dongen GA; Trachsel E; Begent RH; Pedley RB
    Br J Cancer; 2007 Jun; 96(12):1862-70. PubMed ID: 17519905
    [TBL] [Abstract][Full Text] [Related]  

  • 37. MicroRNA-494 acts as a tumor suppressor in pancreatic cancer, inhibiting epithelial-mesenchymal transition, migration and invasion by binding to SDC1.
    Yang Y; Tao X; Li CB; Wang CM
    Int J Oncol; 2018 Sep; 53(3):1204-1214. PubMed ID: 29956739
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Syndecan-1 expression is associated with tumor size and EGFR expression in colorectal carcinoma: a clinicopathological study of 230 cases.
    Kim SY; Choi EJ; Yun JA; Jung ES; Oh ST; Kim JG; Kang WK; Lee SH
    Int J Med Sci; 2015; 12(2):92-9. PubMed ID: 25589885
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Augmentation of antitumor activity of an antibody-interleukin 2 immunocytokine with chemotherapeutic agents.
    Holden SA; Lan Y; Pardo AM; Wesolowski JS; Gillies SD
    Clin Cancer Res; 2001 Sep; 7(9):2862-9. PubMed ID: 11555604
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The antibody-based targeted delivery of interleukin-4 and 12 to the tumor neovasculature eradicates tumors in three mouse models of cancer.
    Hemmerle T; Neri D
    Int J Cancer; 2014 Jan; 134(2):467-77. PubMed ID: 23818211
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.